{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:57:01Z","timestamp":1791327421179,"version":"4.3.1"},"reference-count":172,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.autrev.2015.09.002","type":"journal-article","created":{"date-parts":[[2015,9,16]],"date-time":"2015-09-16T06:30:16Z","timestamp":1442385016000},"page":"71-81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":113,"title":["Management of adverse events in the treatment of patients with immunoglobulin therapy: A review of evidence"],"prefix":"10.1016","volume":"15","author":[{"given":"Patrick","family":"Cherin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Marie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricette","family":"Michallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Pelus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Dantal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Charles","family":"Crave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Delain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Viallard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2015.09.002_bb0005","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.iac.2008.06.004","article-title":"History of immunoglobulin replacement","volume":"28","author":"Eibl","year":"2008","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.autrev.2015.09.002_bb0010","doi-asserted-by":"crossref","first-page":"S525","DOI":"10.1016\/j.jaci.2006.01.015","article-title":"Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology","volume":"117","author":"Orange","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0015","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/0090-1229(82)90022-8","article-title":"Use of intravenous gamma-globulin in antibody immunodeficiency: results of a multicenter controlled trial","volume":"22","author":"Ammann","year":"1982","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0020","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1056\/NEJM199107113250207","article-title":"The use of intravenous immune globulin in immunodeficiency diseases","volume":"325","author":"Buckley","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2015.09.002_bb0025","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1067\/mai.2002.124999","article-title":"Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency","volume":"109","author":"Busse","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0030","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1006\/clim.1999.4725","article-title":"Common variable immunodeficiency: clinical and immunological features of 248 patients","volume":"92","author":"Cunningham-Rundles","year":"1999","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0035","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00005792-198505000-00001","article-title":"X-linked agammaglobulinemia: an analysis of 96 patients","volume":"64","author":"Lederman","year":"1985","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2015.09.002_bb0040","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0002-9343(85)90006-3","article-title":"Benefit of intravenous IgG replacement in hypogammaglobulinemic patients with chronic sinopulmonary disease","volume":"79","author":"Roifman","year":"1985","journal-title":"Am J Med"},{"key":"10.1016\/j.autrev.2015.09.002_bb0045","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/01.md.0000100046.06009.b0","article-title":"The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients","volume":"82","author":"Winkelstein","year":"2003","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2015.09.002_bb0050","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1056\/NEJM198810063191403","article-title":"Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia","volume":"319","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2015.09.002_bb0055","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM199107113250201","article-title":"Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. The National Institute of Child Health and Human Developments Intravenous Immunoglobulin Study Group","volume":"325","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2015.09.002_bb0060","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pharmthera.2004.04.002","article-title":"The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile","volume":"102","author":"Dalakas","year":"2004","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.autrev.2015.09.002_bb0065","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","article-title":"High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood","volume":"1","author":"Imbach","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2015.09.002_bb0070","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/S0140-6736(83)91109-1","article-title":"High-dose intravenous gammaglobulin for Kawasaki disease","volume":"2","author":"Furusho","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2015.09.002_bb0075","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/ana.1088","article-title":"Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"50","author":"Hughes","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0080","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0140-6736(96)09095-2","article-title":"Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain\u2013Barre syndrome. Plasma Exchange\/Sandoglobulin Guillain\u2013Barre Syndrome Trial Group","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2015.09.002_bb0085","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/0002-9343(91)90009-M","article-title":"Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients","volume":"91","author":"Cherin","year":"1991","journal-title":"Am J Med"},{"key":"10.1016\/j.autrev.2015.09.002_bb0090","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/0140-6736(90)91630-S","article-title":"Intravenous immunoglobulin for polymyositis and dermatomyositis","volume":"336","author":"Cherin","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2015.09.002_bb0095","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.autrev.2015.04.002","article-title":"Kawasaki disease: an evolving paradigm","volume":"14","author":"Greco","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.09.002_bb0100","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.autrev.2014.08.018","article-title":"Subcutaneous IgG in immune-mediate diseases: proposed mechanisms of action and literature review","volume":"13","author":"Danieli","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.09.002_bb0105","doi-asserted-by":"crossref","first-page":"721","DOI":"10.7326\/0003-4819-126-9-199705010-00008","article-title":"Intravenous immune globulin therapy for neurologic diseases","volume":"126","author":"Dalakas","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2015.09.002_bb0110","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.autrev.2015.03.005","article-title":"Granulomatosis with polyangiitis and intravenous immunoglobulins: a case series and review of the literature","volume":"14","author":"Guidelli","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.09.002_bb0115","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.autrev.2015.04.003","article-title":"The role of intravenous immunoglobulins in the treatment of rheumatoid arthritis","volume":"14","author":"Katz-Agranov","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.09.002_bb0120","article-title":"Guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg)","author":"EMA","year":"2010"},{"key":"10.1016\/j.autrev.2015.09.002_bb0125","article-title":"Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous and\/or intramuscular administration (SCIg\/IMIg)","author":"EMA","year":"2012"},{"key":"10.1016\/j.autrev.2015.09.002_bb0130","article-title":"Rapport public d'\u00e9valuation: GAMMANORM, 165mg\/ml solution pour injection (voie sous-cutan\u00e9e et intramusculaire)","author":"afssaps","year":"2005"},{"key":"10.1016\/j.autrev.2015.09.002_bb0135","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1023\/A:1006678312925","article-title":"The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy","volume":"20","author":"Chapel","year":"2000","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2004.02.002","article-title":"Subcutaneous immunoglobulin replacement in primary immunodeficiencies","volume":"112","author":"Berger","year":"2004","journal-title":"Clin Immunol"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2015.09.002_bb0145","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2249.2009.04027.x","article-title":"Subcutaneous immunoglobulin: opportunities and outlook","volume":"158","author":"Misbah","year":"2009","journal-title":"Clin Exp Immunol"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2015.09.002_bb0150","first-page":"79","article-title":"Side-effects of intravenous immune globulins","volume":"97","author":"Duhem","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0155","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJM199201093260206","article-title":"Manipulating the immune system with immune globulin","volume":"326","author":"Dwyer","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2015.09.002_bb0160","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJM199412153312409","article-title":"Transmission of viral infections through intravenous immune globulin","volume":"331","author":"Schiff","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2015.09.002_bb0165","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/S1567-5769(03)00134-6","article-title":"Comparison of the efficacy of IGIV-C, 10% (caprylate\/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial","volume":"3","author":"Roifman","year":"2003","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0170","doi-asserted-by":"crossref","first-page":"78S","DOI":"10.1592\/phco.2005.25.11part2.78S","article-title":"The product: all intravenous immunoglobulins are not equivalent","volume":"25","author":"Siegel","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.autrev.2015.09.002_bb0175","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.iac.2008.06.002","article-title":"Intravenous immunoglobulins: evolution of commercial IVIG preparations","volume":"28","author":"Hooper","year":"2008","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.autrev.2015.09.002_bb0180","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2165\/11537660-000000000-00000","article-title":"Relevant criteria for selecting an intravenous immunoglobulin preparation for clinical use","volume":"24","author":"Cherin","year":"2010","journal-title":"BioDrugs"},{"issue":"Suppl. 15","key":"10.1016\/j.autrev.2015.09.002_bb0185","first-page":"S53","article-title":"Safety and side effects of I.V. immunoglobulin therapy","volume":"14","author":"Nydegger","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0190","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1385\/CRIAI:29:3:173","article-title":"Intravenous immunoglobulin: adverse effects and safe administration","volume":"29","author":"Orbach","year":"2005","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0195","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.intimp.2005.11.004","article-title":"Safety considerations in IGIV utilization","volume":"6","author":"Siegel","year":"2006","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0200","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.tmrv.2013.05.004","article-title":"Adverse effects of human immunoglobulin therapy","volume":"27","author":"Stiehm","year":"2013","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.autrev.2015.09.002_bb0205","first-page":"348","article-title":"Developing clinical guidelines","volume":"170","author":"Shekelle","year":"1999","journal-title":"West J Med"},{"key":"10.1016\/j.autrev.2015.09.002_bb0210","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2015.09.002_bb0215","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1046\/j.1365-2249.2003.02199.x","article-title":"Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin","volume":"133","author":"Brennan","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0220","first-page":"139","article-title":"Adverse reactions of prophylactic intravenous immunoglobulin; a 13-year experience with 3004 infusions in Iranian patients with primary immunodeficiency diseases","volume":"19","author":"Dashti-Khavidaki","year":"2009","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0225","series-title":"Treatment experiences and preferences of patients with primary immune deficiency diseases: First National Survey","first-page":"1","author":"IDF","year":"2003"},{"key":"10.1016\/j.autrev.2015.09.002_bb0230","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.intimp.2014.09.015","article-title":"Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions","volume":"23","author":"Bichuetti-Silva","year":"2014","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0235","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fimmu.2015.00011","article-title":"On the dark side of therapies with immunoglobulin concentrates: the adverse events","volume":"6","author":"Spath","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0240","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/(SICI)1097-4598(199911)22:11<1479::AID-MUS3>3.0.CO;2-B","article-title":"Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines","volume":"22","author":"Dalakas","year":"1999","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2015.09.002_bb0245","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1046\/j.1537-2995.2003.00519.x","article-title":"Intravenous immune globulins: an update for clinicians","volume":"43","author":"Knezevic-Maramica","year":"2003","journal-title":"Transfusion"},{"key":"10.1016\/j.autrev.2015.09.002_bb0250","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2165\/00002018-199921030-00003","article-title":"Adverse effects of intravenous immunoglobulin therapy","volume":"21","author":"Nydegger","year":"1999","journal-title":"Drug Saf"},{"key":"10.1016\/j.autrev.2015.09.002_bb0255","doi-asserted-by":"crossref","first-page":"249","DOI":"10.5415\/apallergy.2013.3.4.249","article-title":"Adverse events of intravenous immunoglobulin infusions: a ten-year retrospective study","volume":"3","author":"Palabrica","year":"2013","journal-title":"Asia Pac Allergy"},{"key":"10.1016\/j.autrev.2015.09.002_bb0260","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1001\/jama.1995.03520470073035","article-title":"Recommendations for off-label use of intravenously administered immunoglobulin preparations. University Hospital Consortium Expert Panel for off-label use of polyvalent intravenously administered immunoglobulin preparations","volume":"273","author":"Ratko","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2015.09.002_bb0265","first-page":"440","article-title":"Intravenous immunoglobulin in neurological disease: a specialist review","volume":"72","author":"Wiles","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2015.09.002_bb0270","series-title":"Immunoglobulin therapy for primary immunodeficiency diseases","article-title":"IDF Guide for Nurses","author":"Foundation ID","year":"2012"},{"key":"10.1016\/j.autrev.2015.09.002_bb0275","first-page":"294","article-title":"Adverse reactions to intravenous immunoglobulin therapy","volume":"2","author":"Iagaru","year":"2007","journal-title":"Maedica"},{"key":"10.1016\/j.autrev.2015.09.002_bb0280","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/00129804-200605000-00006","article-title":"Protocol recommendations for administration of intravenous immunoglobulin in Canada","volume":"29","author":"Reid","year":"2006","journal-title":"J Infus Nurs"},{"key":"10.1016\/j.autrev.2015.09.002_bb0285","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0022-510X(97)00292-X","article-title":"Intravenous immunoglobulin treatment of neurological autoimmune diseases","volume":"153","author":"Stangel","year":"1998","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.autrev.2015.09.002_bb0290","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s12026-007-0003-5","article-title":"Safety of IGIV therapy and infusion-related adverse events","volume":"38","author":"Ballow","year":"2007","journal-title":"Immunol Res"},{"key":"10.1016\/j.autrev.2015.09.002_bb0295","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/08916930600825867","article-title":"Long term safety of IVIg therapy in multiple sclerosis: 10years experience","volume":"39","author":"Katz","year":"2006","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2015.09.002_bb0300","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.aller.2012.09.006","article-title":"Guidelines for the use of human immunoglobulin therapy in patients with primary immunodeficiencies in Latin America","volume":"42","author":"Condino-Neto","year":"2014","journal-title":"Allergol Immunopathol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0305","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1212\/WNL.59.12_suppl_6.S33","article-title":"Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immune-mediated neuropathies","volume":"59","author":"Brannagan","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2015.09.002_bb0310","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1212\/WNL.47.3.674","article-title":"Complications of intravenous immune globulin treatment in neurologic disease","volume":"47","author":"Brannagan","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2015.09.002_bb0315","series-title":"Consensus recommendations for the use of immunoglobulin replacement therapy in immune deficiency","author":"Group APIiIE","year":"2009"},{"key":"10.1016\/j.autrev.2015.09.002_bb0320","series-title":"Intravenous immunoglobulin: prevention and treatment of disease","first-page":"1","author":"Statement NC","year":"1990"},{"key":"10.1016\/j.autrev.2015.09.002_bb0325","doi-asserted-by":"crossref","first-page":"844","DOI":"10.2215\/CJN.01701105","article-title":"Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: a single-center experience","volume":"1","author":"Vo","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0330","first-page":"975","article-title":"Intravenous immunoglobulin utilization in a tertiary care teaching hospital in Saudi Arabia","volume":"29","author":"Alangari","year":"2008","journal-title":"Saudi Med J"},{"key":"10.1016\/j.autrev.2015.09.002_bb0335","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.clim.2009.10.003","article-title":"Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: a working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology","volume":"135","author":"Yong","year":"2010","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0340","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/adc.2005.078733","article-title":"A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions","volume":"91","author":"Singh-Grewal","year":"2006","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.autrev.2015.09.002_bb0345","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1365-2249.2004.02412.x","article-title":"Increased risk of adverse events when changing intravenous immunoglobulin preparations","volume":"136","author":"Ameratunga","year":"2004","journal-title":"Clin Exp Immunol"},{"issue":"Suppl. 4","key":"10.1016\/j.autrev.2015.09.002_bb0350","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/CND.0b013e3182212589","article-title":"The safety profile of home infusion of intravenous immunoglobulin in patients with neuroimmunologic disorders","volume":"12","author":"Souayah","year":"2011","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1016\/j.autrev.2015.09.002_bb0355","first-page":"174","article-title":"Use of methylprednisolone as prophylaxis for immediate adverse infusion reactions in hypogammaglobulinaemic patients receiving intravenous immunoglobulin: a controlled trial","volume":"24","author":"Roberton","year":"1988","journal-title":"Aust Paediatr J"},{"key":"10.1016\/j.autrev.2015.09.002_bb0360","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S1081-1206(10)61142-8","article-title":"Practice parameter for the diagnosis and management of primary immunodeficiency","volume":"94","author":"Bonilla","year":"2005","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0365","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.intimp.2005.11.015","article-title":"Adverse events associated with intravenous immunoglobulin therapy","volume":"6","author":"Hamrock","year":"2006","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0370","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1001\/jamadermatol.2014.109","article-title":"Eczematous reaction to intravenous immunoglobulin: an alternative cause of eczema","volume":"150","author":"Miyamoto","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0375","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0887-7963(03)00038-5","article-title":"Risks associated with the use of intravenous immunoglobulin","volume":"17","author":"Pierce","year":"2003","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.autrev.2015.09.002_bb0380","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1345\/aph.1K198","article-title":"Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid","volume":"41","author":"Gurcan","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.autrev.2015.09.002_bb0385","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1056\/NEJM198602273140907","article-title":"Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA","volume":"314","author":"Burks","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2015.09.002_bb0390","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1007\/s10875-012-9720-1","article-title":"Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis","volume":"32","author":"Abolhassani","year":"2012","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0395","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10875-006-9002-x","article-title":"Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies\u2014a prospective, multi-national study","volume":"26","author":"Gardulf","year":"2006","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0400","first-page":"213","article-title":"Substitution therapy in immunodeficient patients with anti-IgA antibodies or severe adverse reactions to previous immunoglobulin therapy","volume":"61","author":"Eijkhout","year":"2003","journal-title":"Neth J Med"},{"key":"10.1016\/j.autrev.2015.09.002_bb0405","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10875-006-9021-7","article-title":"Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases","volume":"26","author":"Ochs","year":"2006","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0410","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.jaci.2004.06.053","article-title":"Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home","volume":"114","author":"Gardulf","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0415","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1111\/j.1651-2227.2007.00485.x","article-title":"Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency","volume":"96","author":"Fasth","year":"2007","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.autrev.2015.09.002_bb0420","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1055\/s-2004-820297","article-title":"Treatment of patients with primary antibody deficiencies in Germany","volume":"217","author":"Borte","year":"2005","journal-title":"Klin Padiatr"},{"key":"10.1016\/j.autrev.2015.09.002_bb0425","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJM199308193290820","article-title":"Recurrent migraine and intravenous immune globulin therapy","volume":"329","author":"Constantinescu","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2015.09.002_bb0430","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1526-4610.1998.3804317.x","article-title":"Successful treatment of headache related to intravenous immunoglobulin with antimigraine medications","volume":"38","author":"Finkel","year":"1998","journal-title":"Headache"},{"key":"10.1016\/j.autrev.2015.09.002_bb0435","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1517\/14740338.4.2.285","article-title":"Drug-induced aseptic meningitis","volume":"4","author":"Hopkins","year":"2005","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.autrev.2015.09.002_bb0440","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/0003-4819-121-4-199408150-00014","article-title":"Aseptic meningitis and intravenous immunoglobulin therapy","volume":"121","author":"Scribner","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2015.09.002_bb0445","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1546-0096-9-28","article-title":"Clinical characteristics of aseptic meningitis induced by intravenous immunoglobulin in patients with Kawasaki disease","volume":"9","author":"Kemmotsu","year":"2011","journal-title":"Pediatr Rheumatol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0450","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1136\/jcp.56.4.308","article-title":"Transverse sinus thrombosis and IVIg treatment: a case report and discussion of risk-benefit assessment for immunoglobulin treatment","volume":"56","author":"Evangelou","year":"2003","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0455","doi-asserted-by":"crossref","first-page":"259","DOI":"10.7326\/0003-4819-121-4-199408150-00004","article-title":"Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors","volume":"121","author":"Sekul","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2015.09.002_bb0460","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/mus.880170620","article-title":"Aseptic meningitis as a complication of intravenous immunoglobulin therapy for myasthenia gravis","volume":"17","author":"Ellis","year":"1994","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2015.09.002_bb0465","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00002018-200022030-00005","article-title":"Drug-induced aseptic meningitis: diagnosis and management","volume":"22","author":"Jolles","year":"2000","journal-title":"Drug Saf"},{"key":"10.1016\/j.autrev.2015.09.002_bb0470","first-page":"539","article-title":"Intravenous immune globulin and aseptic meningitis","volume":"146","author":"Rao","year":"1992","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.autrev.2015.09.002_bb0475","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1179\/acb.2010.057","article-title":"Repeated, severe headache in a lung transplant patient: a case report","volume":"65","author":"Veranneman","year":"2010","journal-title":"Acta Clin Belg"},{"key":"10.1016\/j.autrev.2015.09.002_bb0480","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1592\/phco.2005.25.6.886","article-title":"Intravenous immunoglobulin-associated acute renal failure: case series and literature review","volume":"25","author":"Itkin","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.autrev.2015.09.002_bb0485","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000354893","article-title":"Intravenous immunoglobulins: in-depth review of excipients and acute kidney injury risk","volume":"38","author":"Dantal","year":"2013","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0490","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.semarthrit.2004.06.003","article-title":"Intravenous immunoglobulin and the kidney\u2014a two-edged sword","volume":"34","author":"Orbach","year":"2004","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.09.002_bb0495","first-page":"60","article-title":"Important drug warning: Immune Globulin Intravenous (human) (IGIV) products","volume":"19","author":"Epstein","year":"2000","journal-title":"Neonatal Netw"},{"key":"10.1016\/j.autrev.2015.09.002_bb0500","series-title":"Direction de l'Evaluation des M\u00e9dicaments et des Produits Biologiques \u2014 Unit\u00e9 de Pharmacovigilance","article-title":"Enq\u00eate officielle immunoglobulines humaines: atteintes r\u00e9nales","author":"Pharmacovigilance A-CNd","year":"2006"},{"key":"10.1016\/j.autrev.2015.09.002_bb0505","series-title":"Public Communication\u2014Health Canada endorsed important safety information on Privigen, immune globulin intravenous (human)","author":"Canada CB","year":"2012"},{"key":"10.1016\/j.autrev.2015.09.002_bb0510","doi-asserted-by":"crossref","first-page":"c143","DOI":"10.1159\/000104424","article-title":"Acute renal failure, translocational hyponatremia and hyperkalemia following intravenous immunoglobulin therapy","volume":"106","author":"Daphnis","year":"2007","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.autrev.2015.09.002_bb0515","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/qjmed\/93.11.751","article-title":"Nephrotoxicity of intravenous immunoglobulin","volume":"93","author":"Levy","year":"2000","journal-title":"QJM"},{"key":"10.1016\/j.autrev.2015.09.002_bb0520","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2174\/187231211795305302","article-title":"Serum trough IgG level and annual intravenous immunoglobulin dose are not related to body size in patients on regular replacement therapy","volume":"5","author":"Khan","year":"2011","journal-title":"Drug Metab Lett"},{"key":"10.1016\/j.autrev.2015.09.002_bb0525","doi-asserted-by":"crossref","first-page":"S326","DOI":"10.1016\/j.revmed.2006.10.095","article-title":"Tol\u00e9rance des immunoglobulines polyvalentes, impact de l'uitlisation d'un protocole de prescription sur la survenue d'effets ind\u00e9sirables li\u00e9s au traitement","volume":"27","author":"Grenouillet-Delacre","year":"2006","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.autrev.2015.09.002_bb0530","first-page":"24","article-title":"Effets ind\u00e9sirables li\u00e9s aux immunoglobulines humaines polyvalentes normales: int\u00e9r\u00eat des mesures de pr\u00e9vention","volume":"29","author":"Grenouillet-Delacre","year":"2008","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.autrev.2015.09.002_bb0535","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1345\/aph.1E040","article-title":"Acute renal failure and intravenous immune globulin: occurs with sucrose-stabilized, but not with D-sorbitol-stabilized, formulation","volume":"38","author":"Chapman","year":"2004","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.autrev.2015.09.002_bb0540","first-page":"4","article-title":"Intravenous immunoglobulins and acute renal failure: mechanism and prevention","volume":"28","author":"Fakhouri","year":"2007","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.autrev.2015.09.002_bb0545","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/0002-9343(87)90110-0","article-title":"Acute cryoglobulinemic renal failure after intravenous infusion of gamma globulin","volume":"82","author":"Barton","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.autrev.2015.09.002_bb0550","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00415-009-0969-0","article-title":"Case\u2013control study of thromboembolic events associated with IV immunoglobulin","volume":"256","author":"Caress","year":"2009","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0555","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1111\/j.1537-2995.2012.03589.x","article-title":"Immune globulins and thrombotic adverse events as recorded in a large administrative database in 2008 through 2010","volume":"52","author":"Daniel","year":"2012","journal-title":"Transfusion"},{"key":"10.1016\/j.autrev.2015.09.002_bb0560","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/vox.12025","article-title":"Thromboembolic events associated with immunoglobulin treatment","volume":"105","author":"Funk","year":"2013","journal-title":"Vox Sang"},{"key":"10.1016\/j.autrev.2015.09.002_bb0565","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1365-2133.2006.07390.x","article-title":"Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature","volume":"155","author":"Marie","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0570","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.thromres.2014.03.046","article-title":"Symptomatic thromboembolic events in patients treated with intravenous-immunoglobulins: results from a retrospective cohort study","volume":"133","author":"Ramirez","year":"2014","journal-title":"Thromb Res"},{"key":"10.1016\/j.autrev.2015.09.002_bb0575","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1212\/01.WNL.0000068334.04500.08","article-title":"Arterial thrombosis induced by IVIg and its treatment with tPA","volume":"60","author":"Okuda","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2015.09.002_bb0580","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/ard.59.1.77","article-title":"Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders. A study of four cases","volume":"59","author":"Elkayam","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.09.002_bb0585","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1212\/01.WNL.0000068335.01620.9D","article-title":"The clinical features of 16 cases of stroke associated with administration of IVIg","volume":"60","author":"Caress","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2015.09.002_bb0590","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(04)17101-8","article-title":"Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial","volume":"364","author":"Hommes","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2015.09.002_bb0595","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1160\/TH06-09-0503","article-title":"Intravenous immunoglobulin-associated vena cava thrombosis","volume":"96","author":"Marie","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.autrev.2015.09.002_bb0600","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jns.2011.05.035","article-title":"Thromboembolic complications of intravenous immunoglobulin therapy in patients with neuropathy: a two-year study","volume":"308","author":"Rajabally","year":"2011","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.autrev.2015.09.002_bb0605","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.autrev.2010.03.003","article-title":"Information for healthcare providers on general features of IGIV with emphasis on differences between commercially available products","volume":"9","author":"Gurcan","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.09.002_bb0610","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.aller.2012.09.006","article-title":"Guidelines for the use of human immunoglobulin therapy in patients with primary immunodeficiencies in Latin America","volume":"42","author":"Condino-Neto","year":"2014","journal-title":"Allergol Immunopathol (Madr)"},{"key":"10.1016\/j.autrev.2015.09.002_bb0615","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1212\/01.WNL.0000074394.15882.83","article-title":"Strokes, thromboembolic events, and IVIg: rare incidents blemish an excellent safety record","volume":"60","author":"Dalakas","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2015.09.002_bb0620","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/01.mbc.0000172694.85233.a8","article-title":"Venous and arterial thrombosis following administration of intravenous immunoglobulins","volume":"16","author":"Paran","year":"2005","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.autrev.2015.09.002_bb0625","doi-asserted-by":"crossref","first-page":"278","DOI":"10.18553\/jmcp.2007.13.3.278","article-title":"Expert opinion regarding clinical and other outcome considerations in the formulary review of immune globulin","volume":"13","author":"Sorensen","year":"2007","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.autrev.2015.09.002_bb0630","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1365-2710.2011.01287.x","article-title":"Intravenous immunoglobulin increases plasma viscosity without parallel rise in blood pressure","volume":"37","author":"Bentley","year":"2012","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.autrev.2015.09.002_bb0635","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1212\/WNL.44.2.223","article-title":"High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events","volume":"44","author":"Dalakas","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2015.09.002_bb0640","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/0140-6736(92)90806-E","article-title":"Effect of high-dose intravenous immunoglobulin therapy on blood rheology","volume":"339","author":"Reinhart","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2015.09.002_bb0645","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ajh.10325","article-title":"Intravenous immunoglobulin therapy results in post-infusional hyperproteinemia, increased serum viscosity, and pseudohyponatremia","volume":"73","author":"Steinberger","year":"2003","journal-title":"Am J Hematol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0650","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1423-0410.2012.01648.x","article-title":"In vitro and in vivo properties differ among liquid intravenous immunoglobulin preparations","volume":"104","author":"Dhainaut","year":"2013","journal-title":"Vox Sang"},{"key":"10.1016\/j.autrev.2015.09.002_bb0655","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1423-0410.2011.01502.x","article-title":"Identification of kallikrein and FXIa as impurities in therapeutic immunoglobulins: implications for the safety and control of intravenous blood products","volume":"102","author":"Etscheid","year":"2012","journal-title":"Vox Sang"},{"key":"10.1016\/j.autrev.2015.09.002_bb0660","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1023\/A:1023239904856","article-title":"Anti-DNA and antiphospholipid antibodies in IVIG preparations: in vivo study in naive mice","volume":"18","author":"Krause","year":"1998","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0665","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/1096-8652(200009)65:1<30::AID-AJH5>3.0.CO;2-J","article-title":"Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations","volume":"65","author":"Wolberg","year":"2000","journal-title":"Am J Hematol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0670","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0140-6736(86)92511-0","article-title":"Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients","volume":"2","author":"Woodruff","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2015.09.002_bb0675","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.biologicals.2014.04.002","article-title":"Quantifying the thrombogenic potential of human plasma-derived immunoglobulin products","volume":"42","author":"Germishuizen","year":"2014","journal-title":"Biologicals"},{"key":"10.1016\/j.autrev.2015.09.002_bb0680","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/vox.12119","article-title":"Assessment of the ability of the Privigen(R) purification process to deplete thrombogenic factor XIa from plasma","volume":"107","author":"Komenda","year":"2014","journal-title":"Vox Sang"},{"key":"10.1016\/j.autrev.2015.09.002_bb0685","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/000331970205300117","article-title":"Intravenous immunoglobulin-related acute coronary syndrome and coronary angiography in idiopathic thrombocytopenic purpura\u2014a case report and literature review","volume":"53","author":"Crouch","year":"2002","journal-title":"Angiology"},{"key":"10.1016\/j.autrev.2015.09.002_bb0690","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/ajh.2830440321","article-title":"Deleterious effects of intravenous immunoglobulin in a patient with thrombotic thrombocytopenic purpura","volume":"44","author":"Durand","year":"1993","journal-title":"Am J Hematol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0695","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1212\/WNL.57.9.1699","article-title":"Rapid infusion of intravenous immune globulin in patients with neuromuscular disorders","volume":"57","author":"Grillo","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2015.09.002_bb0700","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1182\/blood.V84.7.2136.2136","article-title":"Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo","volume":"84","author":"Aukrust","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2015.09.002_bb0705","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1046\/j.1423-0410.1998.7420074.x","article-title":"IVIG adverse reactions: potential role of cytokines and vasoactive substances","volume":"74","author":"Bagdasarian","year":"1998","journal-title":"Vox Sang"},{"key":"10.1016\/j.autrev.2015.09.002_bb0710","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1046\/j.1365-3083.1998.00386.x","article-title":"High-dose intravenous immunoglobulin treatment activates complement in vivo","volume":"48","author":"Mollnes","year":"1998","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0715","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000056085","article-title":"Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases","volume":"62","author":"Sherer","year":"2001","journal-title":"Pharmacology"},{"key":"10.1016\/j.autrev.2015.09.002_bb0720","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1423-0410.2009.01217.x","article-title":"In vitro comparison of the complement-scavenging capacity of different intravenous immunoglobulin preparations","volume":"97","author":"Spycher","year":"2009","journal-title":"Vox Sang"},{"key":"10.1016\/j.autrev.2015.09.002_bb0725","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0955-3886(98)00055-1","article-title":"Effect of intravenous immunoglobulin therapy on plasma complement","volume":"19","author":"Wegmuller","year":"1998","journal-title":"Transfus Sci"},{"key":"10.1016\/j.autrev.2015.09.002_bb0730","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000008040","article-title":"High-dose intravenous immunoglobulin treatment and cerebral vasospasm: A possible mechanism of ischemic encephalopathy?","volume":"41","author":"Sztajzel","year":"1999","journal-title":"Eur Neurol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0735","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/WNL.46.1.250","article-title":"Reversible encephalopathy with cerebral vasospasm in a Guillain\u2013Barre syndrome patient treated with intravenous immunoglobulin","volume":"46","author":"Voltz","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2015.09.002_bb0740","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2230.2008.02809.x","article-title":"Analysis of thromboembolic risk related to high-dose intravenous immunoglobulin treatment: a preliminary clinical study of 10 patients with autoimmune mucocutaneous blistering diseases","volume":"34","author":"Mignogna","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0745","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1440-1797.2010.01399.x","article-title":"Slow and steady. Reducing thrombotic events in renal transplant recipients treated with IVIg for antibody-mediated rejection","volume":"16","author":"Huang","year":"2011","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.autrev.2015.09.002_bb0750","first-page":"75","article-title":"Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke","volume":"10","author":"Chapman","year":"2014","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.autrev.2015.09.002_bb0755","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1111\/j.1537-2995.2008.01721.x","article-title":"Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis","volume":"48","author":"Daw","year":"2008","journal-title":"Transfusion"},{"key":"10.1016\/j.autrev.2015.09.002_bb0760","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1546-0096-10-10","article-title":"Hemolytic anemia following intravenous immunoglobulin therapy in patients treated for Kawasaki disease: a report of 4 cases","volume":"10","author":"Berard","year":"2012","journal-title":"Pediatr Rheumatol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0765","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.2215\/CJN.04540709","article-title":"Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients","volume":"4","author":"Kahwaji","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0770","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3109\/s10165-004-0316-3","article-title":"An infant with gamma-globulin-induced hypersensitivity syndrome who developed Evans' syndrome after a second gamma-globulin treatment","volume":"14","author":"Miyamae","year":"2004","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0775","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/(SICI)1096-8652(200003)63:3<160::AID-AJH11>3.0.CO;2-4","article-title":"Severe hemolytic anemia following high-dose intravenous immunoglobulin administration in a patient with Kawasaki disease","volume":"63","author":"Nakagawa","year":"2000","journal-title":"Am J Hematol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0780","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1423-0410.1991.tb00898.x","article-title":"Defining the specificity of anti-A\/B IgM\/G antibodies with different antigens and lectins","volume":"60","author":"Buchs","year":"1991","journal-title":"Vox Sang"},{"key":"10.1016\/j.autrev.2015.09.002_bb0785","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1046\/j.1537-2995.1990.30590296378.x","article-title":"Hemolysis after intravenous immune globulin therapy: relation to IgG subclasses of red cell antibody","volume":"30","author":"Okubo","year":"1990","journal-title":"Transfusion"},{"key":"10.1016\/j.autrev.2015.09.002_bb0790","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/(SICI)1097-4598(199709)20:9<1142::AID-MUS8>3.0.CO;2-8","article-title":"Hemolytic anemia associated with intravenous immunoglobulin","volume":"20","author":"Wilson","year":"1997","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2015.09.002_bb0795","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0192-0561(99)00020-X","article-title":"Neutropenia as a complication of intravenous immunoglobulin (IVIG) therapy in children with immune thrombocytopenic purpura: common and non-alarming","volume":"21","author":"Berkovitch","year":"1999","journal-title":"Int J Immunopharmacol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0800","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/01.mph.0000155871.26380.84","article-title":"Neutropenia following IVIG therapy in pediatric patients with immune-mediated thrombocytopenia","volume":"27","author":"Niebanck","year":"2005","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0805","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0165-5728(95)00167-0","article-title":"Neutropenia in a patient receiving intravenous immune globulin","volume":"64","author":"Tam","year":"1996","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0810","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1182\/blood-2006-05-021568","article-title":"Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations","volume":"108","author":"von Gunten","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2015.09.002_bb0815","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/00002826-200311000-00009","article-title":"Neutropenia as a complication of high-dose intravenous immunoglobulin therapy in adult patients with neuroimmunologic disorders","volume":"26","author":"Matsuda","year":"2003","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0820","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.patbio.2004.06.001","article-title":"Transfusion related acute lung injury (TRALI): an unrecognised pathology","volume":"53","author":"Moalic","year":"2005","journal-title":"Pathol Biol (Paris)"},{"key":"10.1016\/j.autrev.2015.09.002_bb0825","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/ajh.21185","article-title":"Transfusion-related acute lung injury following intravenous anti-D administration in an adolescent","volume":"83","author":"Berger-Achituv","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0830","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0248-8663(98)80869-2","article-title":"A rare cause of intra-alveolar hemorrhage: a transfusion-related incident with leukoagglutination due to antigranulocyte antibodies (Trali syndrome)","volume":"19","author":"Cailleux","year":"1998","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.autrev.2015.09.002_bb0835","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1046\/j.1537-2995.2001.41020264.x","article-title":"Transfusion-related acute lung injury after the infusion of IVIG","volume":"41","author":"Rizk","year":"2001","journal-title":"Transfusion"},{"key":"10.1016\/j.autrev.2015.09.002_bb0840","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2165\/00128071-200708050-00004","article-title":"Variations in serum hemoglobin, albumin, and electrolytes in patients receiving intravenous immunoglobulin therapy: a real clinical threat?","volume":"8","author":"Mignogna","year":"2007","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0845","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1177\/096120339900800617","article-title":"Intravenous immunoglobulin infusion causing pseudohyponatremia","volume":"8","author":"Ng","year":"1999","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2015.09.002_bb0850","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s10157-006-0416-9","article-title":"True hyponatremia secondary to intravenous immunoglobulin","volume":"10","author":"Nguyen","year":"2006","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0855","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1006\/clim.2001.5132","article-title":"Outcome of intravenous immunoglobulin-transmitted hepatitis C virus infection in primary immunodeficiency","volume":"101","author":"Razvi","year":"2001","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2015.09.002_bb0860","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0002-9343(92)90247-9","article-title":"Ischemic Vernet's syndrome in giant cell arteritis: first two cases","volume":"93","author":"Cherin","year":"1992","journal-title":"Am J Med"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997215001974?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997215001974?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T10:47:31Z","timestamp":1599562051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997215001974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":172,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S1568997215001974"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2015.09.002","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of adverse events in the treatment of patients with immunoglobulin therapy: A review of evidence","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2015.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}